ATE534381T1 - Pharmazeutische cetp-inhibitor-zusammensetzungen - Google Patents
Pharmazeutische cetp-inhibitor-zusammensetzungenInfo
- Publication number
- ATE534381T1 ATE534381T1 AT04721345T AT04721345T ATE534381T1 AT E534381 T1 ATE534381 T1 AT E534381T1 AT 04721345 T AT04721345 T AT 04721345T AT 04721345 T AT04721345 T AT 04721345T AT E534381 T1 ATE534381 T1 AT E534381T1
- Authority
- AT
- Austria
- Prior art keywords
- cetp inhibitor
- pharmaceutical
- inhibitor compositions
- pharmaceutical compositions
- inhibitor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/82—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45529303P | 2003-03-17 | 2003-03-17 | |
US46052103P | 2003-04-04 | 2003-04-04 | |
US47720203P | 2003-06-10 | 2003-06-10 | |
US49364903P | 2003-08-08 | 2003-08-08 | |
PCT/JP2004/003585 WO2004082593A2 (en) | 2003-03-17 | 2004-03-17 | Pharmaceutical compositions of cetp inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE534381T1 true ATE534381T1 (de) | 2011-12-15 |
Family
ID=33033290
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT04721345T ATE534381T1 (de) | 2003-03-17 | 2004-03-17 | Pharmazeutische cetp-inhibitor-zusammensetzungen |
Country Status (21)
Country | Link |
---|---|
US (2) | US20040225018A1 (de) |
EP (2) | EP1603553B9 (de) |
JP (2) | JP5546715B2 (de) |
KR (2) | KR20080008440A (de) |
AT (1) | ATE534381T1 (de) |
AU (1) | AU2004222434B2 (de) |
BR (1) | BRPI0408466B8 (de) |
CA (1) | CA2519432C (de) |
CO (1) | CO5640101A2 (de) |
CY (1) | CY1112324T1 (de) |
DK (1) | DK1603553T3 (de) |
ES (1) | ES2377121T3 (de) |
HK (1) | HK1084882A1 (de) |
IL (1) | IL170749A (de) |
MX (1) | MXPA05009848A (de) |
NO (1) | NO336891B1 (de) |
NZ (1) | NZ542852A (de) |
PL (1) | PL1603553T3 (de) |
PT (1) | PT1603553E (de) |
SI (1) | SI1603553T1 (de) |
WO (1) | WO2004082593A2 (de) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7718644B2 (en) | 2004-01-22 | 2010-05-18 | The Trustees Of Columbia University In The City Of New York | Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof |
US8022058B2 (en) | 2000-05-10 | 2011-09-20 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
US7879840B2 (en) | 2005-08-25 | 2011-02-01 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
US7186735B2 (en) * | 2002-08-07 | 2007-03-06 | Sanofi-Aventis Deutschland Gmbh | Acylated arylcycloalkylamines and their use as pharmaceuticals |
ATE534381T1 (de) * | 2003-03-17 | 2011-12-15 | Japan Tobacco Inc | Pharmazeutische cetp-inhibitor-zusammensetzungen |
BRPI0408442A (pt) * | 2003-03-17 | 2006-04-04 | Japan Tobacco Inc | método para aumento da biodisponibilidade oral de s-[2-([[1-(2-etilbutil)ciclohexil]carbonil]amino)fenil]2- metilpropanotioato |
TWI393560B (zh) * | 2003-05-02 | 2013-04-21 | Japan Tobacco Inc | 包含s-〔2(〔〔1-(2-乙基丁基)環己基〕羰基〕胺基)苯基〕2-甲基丙烷硫酯及hmg輔酶a還原酶抑制劑之組合 |
NZ546732A (en) * | 2003-09-26 | 2009-10-30 | Japan Tobacco Inc | Method of inhibiting remnant lipoprotein production |
US8710045B2 (en) | 2004-01-22 | 2014-04-29 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the ryanodine receptors |
DOP2005000123A (es) | 2004-07-02 | 2011-07-15 | Merck Sharp & Dohme | Inhibidores de cetp |
WO2006098394A1 (ja) * | 2005-03-14 | 2006-09-21 | Japan Tobacco Inc. | 脂質吸収抑制方法および脂質吸収抑制剤 |
US7704990B2 (en) | 2005-08-25 | 2010-04-27 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
CN103735515A (zh) | 2006-02-09 | 2014-04-23 | 默沙东公司 | Cetp抑制剂的聚合物制剂 |
SG2013089776A (en) * | 2008-12-08 | 2015-07-30 | Hoffmann La Roche | Combined drug administration |
CN102293734A (zh) * | 2010-06-25 | 2011-12-28 | 江苏恒瑞医药股份有限公司 | 托伐普坦固体分散体及其制备方法 |
CN103200935A (zh) | 2010-11-04 | 2013-07-10 | 霍夫曼-拉罗奇有限公司 | 包含2-甲基丙硫代酸s-[2-([[1-(2-乙基丁基)-环己基]-羰基]氨基)苯基]酯和交联羧甲基纤维素钠的组合物 |
RU2013129777A (ru) | 2010-12-08 | 2015-01-20 | Ф. Хоффманн-Ля Рош Аг | Липосомальный препарат далцетрапиба |
EP2675434A1 (de) * | 2011-02-17 | 2013-12-25 | F.Hoffmann-La Roche Ag | Verfahren zur kontrollierten kristallisierung eines wirkstoffes aus einem unterkühlten flüssigkeitszustand durch schmelzextrusion |
WO2015091410A1 (en) | 2013-12-19 | 2015-06-25 | F. Hoffmann-La Roche Ag | Cetp modulator for use in the treatment of eye disease |
JP2021534236A (ja) * | 2018-08-09 | 2021-12-09 | ダルコア ファーマ ユーケー リミテッド,レザーヘッド,ツーク ブランチ | 新規発症2型糖尿病の発生遅延並びに2型糖尿病の進行緩徐化及び治療の方法 |
WO2023064794A1 (en) * | 2021-10-12 | 2023-04-20 | Hdl Therapeutics, Inc. | Methods and systems for prophylactically preventing, slowing the progression of, or treating cerebral amyloid angiopathy, alzheimer's disease and/or acute stroke |
Family Cites Families (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US36520A (en) * | 1862-09-23 | Improvement in the manufacture of tobacco | ||
US36481A (en) * | 1862-09-16 | Improvement in apparatus for distilling petroleum and other oils | ||
US3576830A (en) * | 1966-08-12 | 1971-04-27 | Sumitomo Chemical Co | Amides containing sulfur |
US4346277A (en) * | 1979-10-29 | 1982-08-24 | Eaton Corporation | Packaged electrical heating element |
US4444784A (en) * | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
US5354772A (en) * | 1982-11-22 | 1994-10-11 | Sandoz Pharm. Corp. | Indole analogs of mevalonolactone and derivatives thereof |
US4681893A (en) * | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
US4740438A (en) * | 1986-12-10 | 1988-04-26 | Eastman Kodak Company | Organic disulfides as image dye stabilizers |
US4853319A (en) * | 1986-12-22 | 1989-08-01 | Eastman Kodak Company | Photographic silver halide element and process |
JP2569746B2 (ja) * | 1987-08-20 | 1997-01-08 | 日産化学工業株式会社 | キノリン系メバロノラクトン類 |
US5356869A (en) * | 1987-09-28 | 1994-10-18 | Arch Development Corporation | Metal oxide superconducting powder comprised of flake-like single crystal particles |
US5030447A (en) * | 1988-03-31 | 1991-07-09 | E. R. Squibb & Sons, Inc. | Pharmaceutical compositions having good stability |
US5180589A (en) * | 1988-03-31 | 1993-01-19 | E. R. Squibb & Sons, Inc. | Pravastatin pharmaceuatical compositions having good stability |
US5118583A (en) * | 1988-10-12 | 1992-06-02 | Mitsubishi Paper Mills Limited | Processing composition for printing plate |
FI94339C (fi) * | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
US5622985A (en) * | 1990-06-11 | 1997-04-22 | Bristol-Myers Squibb Company | Method for preventing a second heart attack employing an HMG CoA reductase inhibitor |
FR2665450B1 (fr) * | 1990-08-01 | 1994-04-08 | Rhone Poulenc Chimie | Procede de preparation de dispersions aqueuses de copolymeres. |
JP2648897B2 (ja) * | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | ピリミジン誘導体 |
US5519001A (en) * | 1991-12-19 | 1996-05-21 | Southwest Foundation For Biomedical Research | CETP inhibitor polypeptide antibodies against the synthetic polypeptide and prophylactic and therapeutic anti-atherosclerosis treatments |
EP0618803A4 (de) * | 1991-12-19 | 1995-03-22 | Southwest Found Biomed Res | Polypeptide als inhibitoren gegen cholesterylester-transferase, antikörper gegen die synthetischen polypeptide und prophylaktische und therapeutische behandlungsweisen der atherosklerose. |
US5217859A (en) * | 1992-04-16 | 1993-06-08 | Eastman Kodak Company | Aqueous, solid particle dispersions of dichalcogenides for photographic emulsions and coatings |
US5219721A (en) * | 1992-04-16 | 1993-06-15 | Eastman Kodak Company | Silver halide photographic emulsions sensitized in the presence of organic dichalcogenides |
EP0680320B1 (de) * | 1993-01-19 | 1999-04-14 | Warner-Lambert Company | Stabilisierte, oral anzuwendende zusammensetzung enthaltend die verbindung ci-981 und verfahren |
US5350667A (en) * | 1993-06-17 | 1994-09-27 | Eastman Kodak Company | Photographic elements containing magenta couplers and process for using same |
IL110151A (en) * | 1993-06-30 | 1998-10-30 | Sankyo Co | Amid and urea histories and pharmaceutical preparations containing them |
EP0706508A1 (de) * | 1993-06-30 | 1996-04-17 | The Wellcome Foundation Limited | Diaryl verbindungen als antiatherosklerotische mittel |
US5446207A (en) * | 1993-09-01 | 1995-08-29 | Harbor Branch Oceanographic Institution, Inc. | Anti-dyslipidemic agents |
US5996156A (en) * | 1995-01-31 | 1999-12-07 | Kelley Company, Inc. | Dock leveler raised by deflating an inflatable member |
US5459154A (en) * | 1993-11-08 | 1995-10-17 | American Home Products Corporation | N-hydroxyureas as 5-lipoxygenase inhibitors and inhibitors of oxidative modification of low density lipoprotein |
US5405969A (en) * | 1993-12-10 | 1995-04-11 | Eastman Kodak Company | Manufacture of thioether compounds |
JP3304189B2 (ja) * | 1994-03-18 | 2002-07-22 | マツダ株式会社 | 加硫スクラップゴムを含有する成形用ゴム組成物及びその製造方法 |
US5654134A (en) * | 1994-05-18 | 1997-08-05 | Fuji Photo Film Co., Ltd. | Silver halide emulsion |
DE4428457C1 (de) * | 1994-08-11 | 1995-10-05 | Bayer Ag | Geformte, paraffinhaltige Mastiziermittel |
WO1996015141A1 (en) * | 1994-11-12 | 1996-05-23 | Lg Chemical Ltd. | Cholesteryl ester transfer protein inhibitor peptides and prophylactic and therapeutic anti-arteriosclerosis agents |
EP0720983B1 (de) * | 1994-12-26 | 2001-03-14 | Nisshin Flour Milling Co., Ltd. | Diphenyl-disulfid Verbindungen |
DE19610932A1 (de) * | 1996-03-20 | 1997-09-25 | Bayer Ag | 2-Aryl-substituierte Pyridine |
HRP970330B1 (en) * | 1996-07-08 | 2004-06-30 | Bayer Ag | Cycloalkano pyridines |
DE19627431A1 (de) * | 1996-07-08 | 1998-01-15 | Bayer Ag | Heterocyclisch kondensierte Pyridine |
US6207671B1 (en) * | 1996-07-08 | 2001-03-27 | Bayer Aktiengesellschaft | Cycloalkano-pyridines |
AR008789A1 (es) | 1996-07-31 | 2000-02-23 | Bayer Corp | Piridinas y bifenilos substituidos |
JP3290962B2 (ja) * | 1997-02-12 | 2002-06-10 | 日本たばこ産業株式会社 | Cetp活性阻害剤 |
JP2894445B2 (ja) | 1997-02-12 | 1999-05-24 | 日本たばこ産業株式会社 | Cetp活性阻害剤として有効な化合物 |
IL132797A0 (en) * | 1997-05-14 | 2001-03-19 | Atherogenics Inc | Compounds and methods for the inhibition of the expression of vcam-1 |
US6093573A (en) * | 1997-06-20 | 2000-07-25 | Xoma | Three-dimensional structure of bactericidal/permeability-increasing protein (BPI) |
AU9297798A (en) | 1997-09-16 | 1999-04-05 | G.D. Searle & Co. | Substituted 1,2,4-triazoles useful for inhibiting cholesteryl ester transfer protein activity |
DE19741051A1 (de) | 1997-09-18 | 1999-03-25 | Bayer Ag | Hetero-Tetrahydrochinoline |
MA24643A1 (fr) | 1997-09-18 | 1999-04-01 | Bayer Ag | Tetrahydro-naphtalenes substitues et composes analogues |
US5916595A (en) * | 1997-12-12 | 1999-06-29 | Andrx Pharmaceutials, Inc. | HMG co-reductase inhibitor |
US6605624B1 (en) | 1998-02-13 | 2003-08-12 | Pharmacia Corporation | Substituted pyridines useful for inhibiting cholesteryl ester transfer protein activity |
US6080778A (en) * | 1998-03-23 | 2000-06-27 | Children's Medical Center Corporation | Methods for decreasing beta amyloid protein |
EP0945134A1 (de) * | 1998-03-27 | 1999-09-29 | Boehringer Ingelheim Pharma KG | Neue galenische Zubereitungsformen von Meloxicam zur oralen Applikation |
US6140342A (en) * | 1998-09-17 | 2000-10-31 | Pfizer Inc. | Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines |
GT199900147A (es) | 1998-09-17 | 1999-09-06 | 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas. | |
US6197786B1 (en) * | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
US6147090A (en) | 1998-09-17 | 2000-11-14 | Pfizer Inc. | 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
US6147089A (en) * | 1998-09-17 | 2000-11-14 | Pfizer Inc. | Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
AU2157400A (en) * | 1998-12-23 | 2000-07-31 | G.D. Searle & Co. | Combinations of cholesteryl ester transfer protein inhibitors and hmg coa reductase inhibitors for cardiovascular indications |
DE19917233A1 (de) * | 1999-04-16 | 2000-10-19 | Aventis Pharma Gmbh | Kristalline Formen des Natriumsalzes des 5-Chlor-2-methoxy-N-(2-(4-methoxy-3-methylaminothiocarbonylaminosulfonyl-phenyl)-ethyl)- benzamids |
US20010018446A1 (en) * | 1999-09-23 | 2001-08-30 | G.D. Searle & Co. | Substituted N-Aliphatic-N-Aromatictertiary-Heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity |
US6476075B1 (en) * | 1999-09-23 | 2002-11-05 | G.D. Searle & Co. | Use of substituted N, N-bis-benzyl aminoalcohol compounds inhibiting cholesteryl ester transfer protein activity |
HN2000000203A (es) * | 1999-11-30 | 2001-06-13 | Pfizer Prod Inc | Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas. |
US6242003B1 (en) * | 2000-04-13 | 2001-06-05 | Novartis Ag | Organic compounds |
US7115279B2 (en) | 2000-08-03 | 2006-10-03 | Curatolo William J | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
US7049283B2 (en) * | 2000-12-06 | 2006-05-23 | Novartis Ag | Pharmaceutical compositions for the oral delivery of pharmacologically active agents |
CN100522174C (zh) * | 2001-03-27 | 2009-08-05 | 大日本住友制药株式会社 | 结晶异唑衍生物及其药物制剂 |
CA2455288A1 (en) * | 2001-06-21 | 2003-01-03 | Pfizer Products Inc. | Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors |
EP1269994A3 (de) * | 2001-06-22 | 2003-02-12 | Pfizer Products Inc. | Pharmazeutische Zusammensetzungen die ein Arzneimittel und die Konzentration verbesserende Polymere enthalten |
ATE444060T1 (de) * | 2001-06-22 | 2009-10-15 | Pfizer Prod Inc | Pharmazeutische zusammensetzungen enthaltend dispersionen aus arzneistoffen und neutralen polymeren |
AR038375A1 (es) * | 2002-02-01 | 2005-01-12 | Pfizer Prod Inc | Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo |
US7071210B2 (en) * | 2002-07-02 | 2006-07-04 | Pfizer Inc. | CETP inhibitors in combination with antihypertensive agents and uses thereof |
US20040053842A1 (en) * | 2002-07-02 | 2004-03-18 | Pfizer Inc. | Methods of treatment with CETP inhibitors and antihypertensive agents |
ATE534381T1 (de) * | 2003-03-17 | 2011-12-15 | Japan Tobacco Inc | Pharmazeutische cetp-inhibitor-zusammensetzungen |
-
2004
- 2004-03-17 AT AT04721345T patent/ATE534381T1/de active
- 2004-03-17 DK DK04721345.9T patent/DK1603553T3/da active
- 2004-03-17 AU AU2004222434A patent/AU2004222434B2/en not_active Expired
- 2004-03-17 KR KR1020087000175A patent/KR20080008440A/ko not_active Application Discontinuation
- 2004-03-17 SI SI200431822T patent/SI1603553T1/sl unknown
- 2004-03-17 NZ NZ542852A patent/NZ542852A/en not_active IP Right Cessation
- 2004-03-17 KR KR1020057017449A patent/KR100857759B1/ko active IP Right Grant
- 2004-03-17 MX MXPA05009848A patent/MXPA05009848A/es active IP Right Grant
- 2004-03-17 PL PL04721345T patent/PL1603553T3/pl unknown
- 2004-03-17 US US10/802,220 patent/US20040225018A1/en not_active Abandoned
- 2004-03-17 BR BRPI0408466A patent/BRPI0408466B8/pt active IP Right Grant
- 2004-03-17 PT PT04721345T patent/PT1603553E/pt unknown
- 2004-03-17 EP EP04721345A patent/EP1603553B9/de not_active Expired - Lifetime
- 2004-03-17 WO PCT/JP2004/003585 patent/WO2004082593A2/en active Application Filing
- 2004-03-17 EP EP10179280A patent/EP2289507A1/de not_active Withdrawn
- 2004-03-17 ES ES04721345T patent/ES2377121T3/es not_active Expired - Lifetime
- 2004-03-17 CA CA002519432A patent/CA2519432C/en not_active Expired - Fee Related
- 2004-03-17 JP JP2006507668A patent/JP5546715B2/ja not_active Expired - Lifetime
-
2005
- 2005-09-08 IL IL170749A patent/IL170749A/en active IP Right Grant
- 2005-10-14 CO CO05105279A patent/CO5640101A2/es not_active Application Discontinuation
- 2005-10-14 NO NO20054740A patent/NO336891B1/no not_active IP Right Cessation
-
2006
- 2006-04-28 HK HK06105103.7A patent/HK1084882A1/xx not_active IP Right Cessation
-
2010
- 2010-11-10 JP JP2010252215A patent/JP2011052006A/ja active Pending
-
2012
- 2012-02-06 CY CY20121100126T patent/CY1112324T1/el unknown
-
2013
- 2013-07-26 US US13/951,909 patent/US20140243414A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20054740D0 (no) | Farmasoytiske sammensetninger av CETP inhibitorer | |
DE60235083D1 (de) | Substituierte tetracyclin-verbindungen zur behandlung von malaria | |
NO20041452L (no) | 17-beta-hydroksysteroid-dehydrogenase type 3-inhibitorer for behandling av androgenavhengige sykdommer. | |
IS7691A (is) | Lyfjasamsetningar til að meðhöndla æxli | |
NO20024891D0 (no) | Farmasöytiske sammensetninger | |
DE60223923D1 (de) | Prodrugs von gaba-analoga, zusammensetzungen und ihre verwendungszwecke | |
CY1111489T1 (el) | Ενωσεις για την αναστολη του πρωτεασωματος | |
DE60232251D1 (de) | Pharmazeutische zusammensetzungen zur behandlung von asthma | |
IS8398A (is) | Lyfjasamsetningar til að meðhöndla æxli | |
DE60007095T2 (de) | Calanolide zur hemmung von btk | |
ATE410430T1 (de) | 2,3-dihydro-6-nitroimidazoä2,1- büoxazolverbindungen zur behandlung von tuberkulose | |
ATE508114T1 (de) | Mit n-alkylhydroxamsäuren substituierte isoindolylverbindungen und deren pharmazeutische verwendung | |
IT1318649B1 (it) | Composizioni farmaceutiche per il trattamento di mucositi e stomatiti. | |
CY1109465T1 (el) | Νεες φαρμακευτικες φαρμακοτεχνικες μορφες μονταφινιλης | |
CY1110775T1 (el) | Υποκατεστημενα αμιδια του θειενοπυρρολιου του καρβοξυλικου οξεος, αμιδια της πυρρολοθειαζολης του καρβοξυλικου οξεος και σχετικα αναλογα ως αναστολεις της κινασης i εψιλον της καζεϊνης | |
CY1107158T1 (el) | Νεα παραγωγα της ισοκινολινης, η μεθοδος παρασκευης τους και η χρηση τους για τη θεραπεια των διαταραχων του μελατονινεργικου συστηματος | |
DE60317098D1 (de) | Carbostyril-derivate mit selektiven serotonin-aufnahme inhibitoren, zur behandlung von gemütskrankheiten | |
DE50205466D1 (de) | Substituierte 2,5-diamidoindole als ece-inhibitoren zur behandlung von kardiovaskulären erkrankungen | |
ATE437578T1 (de) | Riechstoff- und geschmackstoffzusammensetzungen | |
DK1133997T3 (da) | Beta-interferon til behandling af immunsygdomme | |
NO20043393L (no) | Identifisering av objekter for levering. | |
DZ3461A1 (fr) | Pro-medicaments d acides amines excitateurs. | |
ITRM20030442A0 (it) | Composizione farmaceutica (stressen) per il trattamento di iperomocisteinemia. | |
ITMI20022308A1 (it) | Proteine per il trattamento di neutropenie. | |
ITMI20022263A1 (it) | Composizioni per il trattamento delle emorroidi. |